Ongoing efforts to develop new compounds with improved safety profiles hold great potential for the future, with peripherally restricted CBR antagonists that do not cross the BBB having shown promise in preclinical studies for the treatment of obesity and metabolic disorders. Here, CNR1 is linked to metabolic disease.